The only constant during a drug launch is change. Despite careful planning, commercial organizations must be ready to pivot in response to rapidly changing markets and regulatory conditions. Acorn AI has developed a robust, flexible, and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape.

This webinar will address key considerations and benefits of working with a cutting-edge data management and insights technology. Additionally, we will explore how leveraging Acorn AI’s Commercial Data Model can enable launch success by:

  • Serving as a single source of truth for commercial operations, market access, IT, and other stakeholders across the enterprise
  • Improving data quality through near real-time data validation and  standardization
  • Delivering a clear set of metrics & KPIs to shape your launch strategy
  • Facilitating quicker implementations to enable a faster path to peak-year sales
  • Seamlessly integrating with a variety of business intelligence tools to ensure insight consistency at all business levels

Featured Speakers

Luke Mann-O'Halloran

Director of Product Management
Acorn AI, by Medidata

Luke Mann-O'Halloran is the Director of Product Management for Commercial Data Solutions at Acorn AI, by Medidata. Luke leads the development of the product suite used by Acorn's services team and their clients to maximize the business impact and value of their data. Based in Boston, Luke has 8 years of experience in commercial analytics and data management, and has also worked in management consulting and in telecommunications. Luke graduated from Dartmouth College with a degree in Mathematics.

Elena Ivancheva

Director of Customer Success
Acorn AI, by Medidata

Elena Ivancheva is a Customer Success Director at Acorn AI. She leads the implementations of commercial data warehouse and analytics solutions for biotech and pharmaceutical customers. Combining deep life sciences domain expertise and cross functional team leadership, Elena has facilitated successful new product launches in specialty oncology and rare disease over the last 10 years. Elena holds a MA in Economics and Finance from Brandeis University and a BS in Biology from Suffolk University.